SinoFresh Healthcare Inc. Announces New Leadership; Experienced Executives to Serve as Chairman and CEO
November 30 2010 - 10:39AM
SinoFresh® HealthCare, Inc., (Pink Sheets:SFSH) announces several
significant changes to the corporate management team including the
election of Thomas Fitzgerald as Chairman of the Board of Directors
and the naming of David R. Olund as President & CEO. The
changes were made as part of a broad based, ongoing corporate
restructuring.
Mr. Fitzgerald, the new Chairman of the Board, has more than 25
years of experience in the biopharmaceutical industry. As an
industry consultant and senior executive, he has provided strategic
advice for a range of early stage companies and turnaround
candidates as well as working with and for well established
domestic and multinational businesses. He has also worked with a
number of research based institutions including the University of
Rochester, the Scripps Institute and Thomas Jefferson University on
the generation and growth of spin out life science business from
their intellectual property. Mr. Fitzgerald has been a member
of the SinoFresh Board since 2008.
Mr. Fitzgerald has also held seats on the Boards of Directors
for a number of public and private entities. During his career, he
has been responsible for the development, regulatory and marketing
strategies, government relations, and intellectual property matters
for biopharmaceutical companies. He has held senior executive
positions for a number of both large and small companies, in the
USA and Europe. Mr. Fitzgerald will be working closely with
Mr. David Olund, the Company's new CEO to establish SinoFresh
HealthCare, Inc. as an industry leader and a global presence.
Mr. Olund, the new CEO, has over 30 years of domestic and
international experience in the financial services industry. He has
had corporate and marketing relationships with companies such as
Sun Life of Canada, The CNA Companies, Western Reserve Life
Assurance, New York Life, LifeUSA Traveler Insurance Company and
Shearson/American Express as well as other companies. Mr. Olund has
held the Registered Securities Principal designation in the past
including the position of President, CEO and Chief Compliance
Officer of an NASD member securities firm. During the last 15
years, his financial consulting work has encompassed assignments
for public and private companies, specializing in alternative
finance markets and corporate development in the United States, as
well as doing significant work in Europe, Asia and Latin America
for private multi-national clients.
Mr. Fitzgerald commented that, "David Olund's experience,
passion and know-how will be indispensable to SinoFresh in growing
the company's business. David has a proven record of
initiating and achieving favorable results form the kinds of steps
that will be essential in achieving our ambitious plans to build
the business and establish the long term shareholder value that
follows from the growth of the business."
Mr. Olund comments, "I am proud to be serving the future needs
of the SinoFresh HealthCare business. I particularly look
forward to a bright and promising future on behalf of our
shareholders. I believe that with the combined backgrounds of our
senior management team and our Board of Directors, will enable us
to fully develop our breakthrough technologies in antiseptic upper
respiratory and topical therapies. SinoFresh is very well
positioned to become a significant player in the healthcare
industry." Mr. Olund was also elected to the Board of Directors as
part of the management realignment. Mr. Fitzgerald and Mr.
Olund replace the out-going Chairman and CEO, Charles Fust, who has
left the company.
SinoFresh HealthCare, Inc. is a publicly traded
company (Pink Sheets:SFSH) based in Venice, Florida, that
manufactures and distributes nasal, oral and topical antiseptic
germ-killing products. SinoFresh products are marketed and
distributed globally through a network of strategic wholesale and
retail partners. SinoFresh Healthcare Inc's, premier product,
SinoFresh Antiseptic Homeopathic Nasal spray has in laboratory
tests shown effective antiseptic capability against a variety of
pathogens such as MRSA, E-Coli, H1N1 and a broad range of other
viruses, molds, fungi and bacteria.
For more information please contact our Investor
Relations department at 941.375.8174
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Our
forward-looking statements express our current expectations or
forecasts of possible future results or events, including
projections of future performance, statements of management's plans
and objectives, future contracts, and forecasts of trends and other
matters. Forward-looking statements speak only as of the date of
this filing, and we undertake no obligation to update or revise
such statements to reflect new circumstances or unanticipated
events as they occur. You can identify these statements by the fact
that they do not relate strictly to historic or current facts and
often use words such as "anticipate", "estimate", "expect",
"believe", "will likely result", "outlook", "project" and other
words and expressions of similar meaning. No assurance can be given
that the results in any forward-looking statements will be achieved
and actual results could be affected by one or more factors, which
could cause them to differ materially. For these statements, we
claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform
Act.
CONTACT: SinoFresh Healthcare Inc.
Investor Relations
941.375.8174